[Pharmacological basis for the therapeutic use of ergot alkaloids].
The main mechanisms of action of ergot alkaloids are discussed. Their clinical use (migraine, uterine haemorrhage, orthostatic hypotension, senile cerebral insufficiency, hyperprolactinaemia or Parkinson's disease) and their adverse effects are explained by an affinity for three kinds of central and peripheral receptors: alpha adrenergic, serotoninergic or dopaminergic receptors.
D000316:Adrenergic alpha-Agonists; D000317:Adrenergic alpha-Antagonists; D004876:Ergot Alkaloids / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D011954:Receptors, Dopamine / Q000378:metabolism; D011985:Receptors, Serotonin / Q000187:drug effects / Q000378:metabolism; D013329:Structure-Activity Relationship
D000316:Adrenergic alpha-Agonists; D000317:Adrenergic alpha-Antagonists; D004876:Ergot Alkaloids; D011954:Receptors, Dopamine; D011985:Receptors, Serotonin
Bases pharmacologiques de l'utilisation thérapeutique des alcaloïdes de l'ergot de seigle.